Virtus Fund Advisers, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 201 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.47 and the average weighting 0.3%.

Quarter-by-quarter ownership
Virtus Fund Advisers, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$39,637
+29.9%
757
+0.9%
0.16%
+45.4%
Q1 2024$30,510
+10.1%
7500.0%0.11%
-37.2%
Q4 2023$27,720
-3.2%
7500.0%0.17%
-15.3%
Q3 2023$28,650
+5.9%
7500.0%0.20%
+6.3%
Q2 2023$27,053
-5.6%
7500.0%0.19%
-5.0%
Q1 2023$28,643
-32.9%
7500.0%0.20%
-34.3%
Q4 2022$42,675
-95.6%
750
-98.5%
0.31%
+2960.0%
Q4 2017$981,000
+1027.6%
48,401
+448.6%
0.01%
+900.0%
Q2 2014$87,0008,8230.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2017
NameSharesValueWeighting ↓
Third Security, LLC 19,816,162$195,784,0009.33%
BB BIOTECH AG 5,846,564$57,764,0002.74%
QVT Financial LP 4,556,090$45,014,0002.44%
Parametrica Management Ltd 29,578$292,0002.21%
SECTORAL ASSET MANAGEMENT INC 4,389,682$43,370,0001.84%
Belmont Global Advisors, Inc. 257,000$2,539,0001.83%
HARVEY CAPITAL MANAGEMENT INC 394,550$3,898,0001.40%
Lombard Odier Asset Management (USA) Corp 1,350,000$13,338,0000.70%
IRIDIAN ASSET MANAGEMENT LLC/CT 6,199,685$61,253,0000.63%
Callan Capital, LLC 199,230$1,968,0000.53%
View complete list of HALOZYME THERAPEUTICS INC shareholders